由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
_pennystock版 - Watch GENZ, SNY approach GENZ for interest of buy out
相关主题
Sanofi makes $18.5 billion all-cash offer for Genzyme讨论贴:降低投资风险的最近操作可行性
盘前动态 -- 美股期指下跌,等待柏南克演说 zt懂疫苗的大牛看看这个新闻对PFE SNY有什么影响
Industry outlook-Pharma and Biotech Industry Outlook - July 2010Re: Can somebody post IBD 50 list? (转载)
中国数据强劲,美股期指劲扬hgsi 还能拿着吗? 谁给分析一下? (转载)
长线"value" player - AEZSGenzyme to cut 1,000 jobs, or 8% of force: reports
大家看看这几个公司被买断的可能性怎么样? (转载)大盘又到了关键点位,提醒一下。
Biotech Calendar: Key Dates for FebruaryISIS (转载)
flu vaccine related stockbank stress test
相关话题的讨论汇总
话题: genzyme话题: genz话题: sanofi话题: research话题: stock
1 (共1页)
g******0
发帖数: 1165
1
YMYD
g******0
发帖数: 1165
2
UPDATE 3-Sanofi makes approach to Genzyme - source
2:37pm EDT
* Sanofi makes early approach to Genzyme - source
* Issues such as price, management have not been discussed
* Genzyme shares up over 17 pct (Adds analyst comments, details on Genzyme
strategy)
By Jessica Hall
NEW YORK, July 23 (Reuters) - French drugmaker Sanofi-Aventis SA (SASY.PA:
Quote, Profile, Research, Stock Buzz), on the hunt for a large acquisition,
is sounding out biotech Genzyme Corp (GENZ.O: Quote, Profile, Research,
Stock Buzz) on a possible deal, a source familiar with the matter said on
Friday.
Shares in Genzyme, which is just beginning to emerge from a manufacturing
crisis that has caused shortages in its supply of drugs for rare disorders,
jumped 17.4 percent to $63.60. The talks were first reported by the Wall
Street Journal.
According to the source, the talks are at an early stage and no deal is
imminent. Issues such as price and management structure have not been
discussed, the source said.
Genzyme's current market capitalization is close to $14 billion, but the
company would be expected to argue for a significant premium to that based
on its drug pipeline, analysts said.
"If you started to use the $20 billion number that has been discussed in the
past, it puts Genzyme closer to $75 (a share)," said RBC Capital Markets
analyst Michael Yee.
Sanofi is feeling the sting of patent expirations on a number of its biggest
products, hurting its profit outlook.
U.S. sales of its colon cancer drug Eloxatin have tumbled following recent
generic launches, and its blockbuster cancer drug Taxotere will lose patent
protection by November in Europe and the United States.
Earlier this month, a source told Reuters that Sanofi was looking at several
U.S. deals, including one or two that could be worth at least $15 billion.
[ID:nLDE6610EX]
Reports of Sanofi's acquisition interest buoyed drugmaker shares at the time
, including Genzyme and Botox maker Allergan Inc (AGN.N: Quote, Profile,
Research, Stock Buzz).
On Friday, Allergan shares slipped about 3 percent, while Biogen Idec Inc (
BIIB.O: Quote, Profile, Research, Stock Buzz) , another target of
speculation, slid over 5 percent. (Reporting by Jessica Hall, Toni Clarke
and Debra Sherman; Writing by Michele Gershberg; Editing by Gerald E.
McCormick and Richard Chang)
1 (共1页)
相关主题
bank stress test长线"value" player - AEZS
美联储决定采取进一步宽松政策大家看看这几个公司被买断的可能性怎么样? (转载)
由于对通胀的担忧,中概估计要歇一阵了Biotech Calendar: Key Dates for February
US HOT STOCKS: Abercrombie, Kroger, Sprint, Collective Brandsflu vaccine related stock
Sanofi makes $18.5 billion all-cash offer for Genzyme讨论贴:降低投资风险的最近操作可行性
盘前动态 -- 美股期指下跌,等待柏南克演说 zt懂疫苗的大牛看看这个新闻对PFE SNY有什么影响
Industry outlook-Pharma and Biotech Industry Outlook - July 2010Re: Can somebody post IBD 50 list? (转载)
中国数据强劲,美股期指劲扬hgsi 还能拿着吗? 谁给分析一下? (转载)
相关话题的讨论汇总
话题: genzyme话题: genz话题: sanofi话题: research话题: stock